BioMed X and Servier have established the first XSeed Labs facility in Europe at the Spartners incubator in Paris-Saclay. The collaboration will develop an AI-empowered platform for sterically guided design of bispecific antibodies, addressing critical constraints in cancer immunotherapy development.
EUROIMMUN (part of Revvity) has added 23 new assays to its portfolio of indirect immunofluorescence assays (IFA) for use on the UNIQO 160, its all-in-one instrument for walkway IFA automation. The new assays extend existing panels for autoantibody diagnostics in rheumatology, vasculitis, hepatology and gastroenterology.
Iron deficiency and iron deficiency anemia are remarkably common worldwide. However, recommended ferritin cut-off concentrations can vary widely and there is room for improvement in standardization across different assay platforms. Dr Katie Troike and Dr Adam McShane (Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA) recently conducted their own re-evaluation of ferritin […]
High performance solution for advanced urine determination
The on-demand solution that saves more than time.
The Modern Critical Care Profile Prime Plus provides the most clinical value of any blood gas/critical care analyzer by adding essential tests for kidney function (BUN, Creatinine, eGFR), plasma volume (ePV), ionized magnesium (iMg) and MCHC.
A comprehensive review of diagnostic and monitoring strategies Delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage is a multifactorial syndrome extending beyond large-vessel vasospasm. This review explores the evolving diagnostic and monitoring landscape, emphasizing a shift toward multimodal monitoring techniques that detect microcirculatory failure, spreading depolarizations, and metabolic distress.
Assessment of minimal residual disease during B-cell precursor acute lymphoblastic leukemia provides a good indication of therapy response and prognosis. This investigation can be done in several ways, including flow cytometry. Techniques in this field have developed in recent years and CLI chatted to Dr van der Velden (Department of Immunology, Erasmus University Medical Center, […]
Researchers at Charité – Universitätsmedizin Berlin have developed crossNN, an artificial intelligence model that can classify more than 170 cancer types using DNA methylation patterns. The system achieves 99.1% precision for brain tumours and 97.8% for pan-cancer classification, working across multiple sequencing platforms including nanopore technology.
A new pressure-driven method for generating individual droplets at microfluidic T-junctions offers precise temporal control over droplet formation. The technique, validated through theoretical modelling and experimental testing, promises to advance lab-on-a-chip technologies for chemical analysis, diagnostics, and biological research applications.
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
